A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
7–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed study B2061014 and who in the investigator's opinion would benefit from long term treatment with DVS SR
Willingness and ability to comply with scheduled visits, treatment plan and procedures
You may not be if
Subject requires precaution against suicide
Subject not in a generally healthy condition
Clareo Health | A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
